Elanco (ELAN)
Health Care · Animal Health · NYSE
Elanco is a pure-play animal health leader focused on innovating treatments and wellness solutions for pets and livestock worldwide.
What Elanco does
Elanco is a global animal health company that develops, manufactures, and markets products for the prevention and treatment of disease in both pets and farm animals. Its portfolio includes a broad range of veterinary pharmaceuticals, vaccines, and animal health additives aimed at improving animal well-being and productivity. The company operates across global markets, focusing on both companion animal health and farm animal health segments.
Themes: animal health, companion animal wellness, livestock productivity, veterinary medicine
Fundamentals
- Price$22.70 as of 2026-10-20 close
- Market cap$11.3B as of 2026-08-03 (share count; price 2026-10-20)
- 1-year return+4.5% 2025-10-20 close $21.72 → 2026-10-20 close $22.70
- P/En/a negative earnings
- Net margin-4.9% FY2025, SEC XBRL
- Gross margin+55.0% FY2025, SEC XBRL
- ROE-3.5% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.56 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+6.2% FY2025, SEC XBRL
- Revenue CAGR (3y)+2.2% SEC XBRL
- Beta1.25 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How ELAN compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ELAN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
40.0 #1077 of 1,265 scored · #132 of 146 in Health Care
Valuation 79th (price to book 1.7) and financial health 46th (debt to equity 0.6, free cash flow margin 6%); weakest is profitability (13th, return on equity -3.5%).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Gross profit | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $1.4B | $798M | $54M | $0.11 | $277M† | $33M† |
| Q1 FY2026 2026-03-31 | $1.4B | $785M | $57M | $0.11 | $13M | $51M |
| Q4 FY2025 2025-12-31 | $1.1B† | $589M† | -$276M† | -$0.56† | $108M† | $62M† |
| Q3 FY2025 2025-09-30 | $1.1B | $607M | -$34M | -$0.07 | $219M† | $92M† |
| Q2 FY2025 2025-06-30 | $1.2B | $713M | $11M | $0.02 | $237M† | $57M† |
| Q1 FY2025 2025-03-31 | $1.2B | $684M | $67M | $0.13 | -$4M | $65M |
| Q4 FY2024 2024-12-31 | $1.0B† | $519M† | -$8M† | -$0.02† | $177M† | $47M† |
| Q3 FY2024 2024-09-30 | $1.0B | $538M | $364M | $0.73 | $162M† | $42M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$530M
- Total debt$3.7B borrowings only; leases excluded
- Net debt$3.1B total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Elanco looks technically
Elanco (ELAN) is trading 4.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 18.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 4.6% below its 200-day average, the long-term trend line — a long-term downtrend | -4.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.20 | $23.20 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.81 | $23.81 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 23.04. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal | 13 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($21.62 to $24.11) — its "stochastic" reading is 43 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 43.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $27.98 | $27.98 |
|---|---|---|
| From the 52-week high | it is 18.9% below its 52-week high (its highest price of the past year) | -18.9% |
| Above the 52-week low | it is 17.0% above its 52-week low (its lowest price of the past year) | +17.0% |
| Below the 52-week high | it is 18.9% below its highest point of the past year | 18.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $37.61 (set on 2018-09-27) | $37.61 |
| Given back of the 52-week move | over the past year its closes ranged ($19.80 to $26.84), and it has recovered roughly a third of its fall from last year’s high — 41% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $24.15 to $24.38. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 41.2% |
| From the all-time high | it is 39.6% below its all-time high | -39.6% |
| Nearest price level | it is sitting right on a support level at $22.62 — a price it turned at three times since 2025-12-18, most recently on 2026-06-11. Since 2024-10-21 it has 12 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $7.88 (set on 2023-05-31) | $7.88 |
| Above the all-time low | it is 188.1% above its all-time low | +188.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.757 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.757 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $21.72 and $23.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $21.72 – $22.61 – $23.50 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (4.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.56× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.8% |
|---|---|---|
| Open gap | it gapped 3.3% below the previous close 52 sessions ago and has not traded back through the level it left behind at 26.22 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.3% |
| Gap filled | a 2.1% gap up opened on 2026-09-17 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 23 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3.61% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.3 percentage points (the stock gained 1.2% while the market gained 1.0%) | +0.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.3 percentage points (the stock lost 9.7% while the market gained 3.6%) | -13.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 12.7 percentage points (the stock lost 4.1% while the market gained 8.5%) | -12.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 10.0 percentage points (the stock gained 4.5% while the market gained 14.6%) | -10.1% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.9% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.6% of the share price. | -3.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $23.77 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -4.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $23.19 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -2.1% |
Double bottom, bullish — forming · entry $25.09 · 51 sessions in
Falling wedge, bullish — broke out · entry $22.65 · 83 sessions in
Price levels it has turned at before
ELAN last closed at $22.70 on 2026-10-20. Since 2024-10-21 it has turned at 12 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $22.62 | Support | 0.3% below the last close | turned there three times · 2025-12-18 to 2026-06-11 |
| $23.15 | Resistance | 2.0% above the last close | turned there four times · 2025-11-12 to 2026-10-06 |
| $22.05 | Support | 2.9% below the last close | turned there twice · 2026-01-02 to 2026-04-02 |
| $23.70 | Resistance | 4.4% above the last close | turned there five times · 2025-11-26 to 2026-09-17 |
| $21.58 | Support | 4.9% below the last close | turned there four times · 2025-10-07 to 2026-10-01 |
| $24.50 | Resistance | 8.0% above the last close | turned there twice · 2026-04-15 to 2026-07-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $23.04.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $19.80 and $21.80 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-10-20.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Broke out to a new 20-day high · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$31.00 range $26.00 – $34.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ELAN
- Consensus EPS estimate$0.2057 next reporting period, as of 2026-10-15
- Estimate change, 30 days-$0.00072 (-0.3%) from $0.2064, on 2026-09-10, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High level of debt which restricts operating flexibility and increases interest rate sensitivity.","Dependence on R&D success and regulatory approvals for new product launches.","Intense competition from generic animal health products and evolving veterinary practices."]
What changed in the latest 10-Q
AI-assisted comparison of ELAN's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05): Under Credelio Quattro, states 'During the current quarter, Credelio Quattro was launched in Australia, Canada and Japan' and adds 'Additional submissions have been made in other key markets, including the EU and the U.K.'
- Newer filing (2026-08-05): Under Befrena, states 'We initiated the phased launch of Befrena during the second quarter of 2026.'
- Newer filing (2026-08-05): Under Restructuring Activities, changes incurred charges figure from $14 million (three months ended March 31, 2026) to $17 million (six months ended June 30, 2026).
- Newer filing (2026-08-05): Under Trade Environment, states Section 122 tariffs 'expired on July 24, 2026' and that the U.S. government implemented new tariffs under Section 301 'which specifically target products associated with forced labor concerns.'
- Newer filing (2026-08-05): Under Trade Environment, states the Section 232 tariffs 'are not expected to apply to us, if at all, until at least September 2026.'
- Newer filing (2026-08-05): Under Trade Environment, changes 'Changes to U.S. trade policy continued in the first quarter of 2026' to 'Changes to U.S. trade policy continued throughout the first half of 2026.'
- Newer filing (2026-08-05): Under Trade Environment, changes 'three months ended March 31, 2026' to 'six months ended June 30, 2026.'
- Newer filing (2026-08-05): Under Business Overview, changes purpose phrasing from 'Go Beyond for animals, our customers, our people, and society' to 'Go Beyond for animals, customers, society and our people.'
- Removed:
- Older filing (2026-05-06): Under Credelio Quattro, states 'In April 2026, Credelio Quattro was launched in Australia, and we received regulatory approval in Canada' and includes 'the EU, Japan and the U.K.' in additional submissions.
- Older filing (2026-05-06): Under Befrena, states 'We anticipate launching Befrena in the second quarter of 2026.'
- Older filing (2026-05-06): Under Trade Environment, states 'These tariffs are not effective until the third quarter of 2026.'
- Older filing (2026-05-06): Under Trade Environment, states 'Changes to U.S. trade policy continued in the first quarter of 2026.'
- Older filing (2026-05-06): Under Trade Environment, states 'three months ended March 31, 2026.'
- Older filing (2026-05-06): Under Trade Environment, contains sentence 'Further, the U.S. presidential administration has sought to implement significant changes to the size and scope of the federal government. Among these changes, certain previously authorized government incenti...' which is truncated in the provided text.
- Reworded:
- Under Credelio Quattro, older filing said Credelio Quattro was launched in Australia in April 2026 and received regulatory approval in Canada; newer filing says during the current quarter it was launched in Australia, Canada and Japan.
- Under Credelio Quattro, older filing listed additional submissions in 'the EU, Japan and the U.K.'; newer filing lists 'the EU and the U.K.' (Japan moved to launched markets).
- Under Befrena, older filing said launch was anticipated in Q2 2026; newer filing says phased launch was initiated during Q2 2026.
- Under Restructuring Activities, older filing reported $14 million incurred during the three months ended March 31, 2026; newer filing reports $17 million incurred during the six months ended June 30, 2026.
- Under Trade Environment, older filing said Section 232 tariffs 'are not effective until the third quarter of 2026'; newer filing says they 'are not expected to apply to us, if at all, until at least September 2026.'
- Under Trade Environment, older filing described trade policy changes as continuing 'in the first quarter of 2026'; newer filing describes them as continuing 'throughout the first half of 2026.'
- Under Trade Environment, older filing stated no material impact on results 'for the three months ended March 31, 2026'; newer filing states 'for the six months ended June 30, 2026.'
- Under Trade Environment, older filing included a sentence beginning 'Further, the U.S. presidential administration has sought to implement significant changes...'; newer filing does not include this sentence (text may be truncated in source).
- Notes:
- The older filing's final sentence in the Trade Environment section is truncated ('...certain previously authorized government incenti'), which may limit completeness of comparison for that section.
- Only the MD&A sections provided were compared; other sections of the filings were not part of this comparison.
Risk Factors
- Added:
- Newer filing (2026-08-05) states cash used for investing activities for the six months ended June 30, 2026, was $170 million, including $76 million paid in April 2026 related to the acquisition of AHV.
- Newer filing (2026-08-05) reports forward-starting interest rate swap agreements with a combined notional amount of $1,450 million becoming effective in August 2026.
- Newer filing (2026-08-05) includes 2025 six-month cash flow comparison data: operating activities $233 million, investing activities $(114) million, financing activities $(104) million, and effect of exchange rate changes $56 million.
- Removed:
- Older filing (2026-05-06) stated subsidiary in Argentina had applied hyperinflationary accounting since 2018, prior to its substantial liquidation in 2024.
- Older filing (2026-05-06) reported 2025 three-month cash flow comparison data: operating activities $(4) million, investing activities $(58) million, financing activities $52 million, and effect of exchange rate changes $29 million.
- Older filing (2026-05-06) reported forward-starting interest rate swap agreements with a combined notional amount of $850 million becoming effective in August 2026.
- Reworded:
- Newer filing (2026-08-05) presents cash flow data for the six months ended June 30, 2026 and 2025; older filing (2026-05-06) presented data for the three months ended March 31, 2026 and 2025.
- Newer filing (2026-08-05) describes the increase in cash provided by operating activities as 'primarily driven by an increase in cash earnings'; older filing (2026-05-06) described the increase as 'primarily driven by an increase in non-cash expenses relative to net income.'
- Newer filing (2026-08-05) describes cash used for financing activities as including '$89 million of early and scheduled repayments of long-term borrowings and $35 million of purchases of common stock for employee tax withholding obligations'; older filing (2026-05-06) did not specify dollar amounts, stating it included 'the purchase of common stock for employee tax withholding obligations and scheduled repayments of long-term borrowings.'
- Newer filing (2026-08-05) references debt as of June 30, 2026; older filing (2026-05-06) references debt as of March 31, 2026.
- Newer filing (2026-08-05) states no significant changes in critical accounting estimates during the six months ended June 30, 2026; older filing (2026-05-06) stated the same for the three months ended March 31, 2026.
- Newer filing (2026-08-05) describes Turkey hyperinflationary accounting for the six months ended June 30, 2026; older filing (2026-05-06) described it for the three months ended March 31, 2026.
- Newer filing (2026-08-05) evaluates disclosure controls as of June 30, 2026; older filing (2026-05-06) evaluated them as of March 31, 2026.
- Newer filing (2026-08-05) states 'During the second quarter of 2026, there were no changes in internal control'; older filing (2026-05-06) stated 'During the first quarter of 2026, there were no changes in internal control.'
- Newer filing (2026-08-05) reports interest rate swap and indebtedness data as of June 30, 2026; older filing (2026-05-06) reported it as of March 31, 2026.
- Newer filing (2026-08-05) describes financing activities for six months ended June 30, 2025, including '$374 million in scheduled and early repayments of long-term borrowings, partially enabled by net proceeds of $290 million from the sale of qualifying future royalties'; older filing (2026-05-06) described three-month 2025 financing activities as including '$85 million in net borrowings on our Securitization Facility.'
- Notes:
- Newer filing text is truncated at 'ITEM 1. LEG'; older filing text is truncated at 'reasona', limiting full comparison of subsequent content.
- Both source passages begin mid-sentence after 'Risk Factors – We have substantial indebtedness', so the risk factor preamble is only partially included.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
5 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 1 sell ($100050) — 1 selling insider
- Last 90 days · read to 2026-10-165 buys ($1M) · 1 sell ($100050) — 5 buying, 1 selling insiders
- Last 180 days · read to 2026-10-167 buys ($2M) · 1 sell ($100050) — 7 buying, 1 selling insiders
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of ELAN within a 30-day window between 2026-08-07 and 2026-08-20. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-15. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ELAN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for ELAN from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ELAN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 141,585,201
- Reported value $3,484,411,810
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ELAN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ELAN had 37,291,528 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
ELAN had 7.46% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.16 days to cover at the same settlement.
- Reported short interest (shares) 37,291,528
- Short interest (% of shares outstanding) 7.46%
- Prior settlement (shares) 31,809,151
- Reported change 17.24%
- Days to cover (reported) 6.16
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Zoetis (ZTS)
- Merck Animal Health (MRK)
- Boehringer Ingelheim Animal Health
- Idexx Laboratories (IDXX)
- Ceva Santé Animale
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ELAN vs…
ELAN shows up in…
Frequently asked questions
What does Elanco (ELAN) do?
Elanco is a global animal health company that develops, manufactures, and markets products for the prevention and treatment of disease in both pets and farm animals. Its portfolio includes a broad range of veterinary pharmaceuticals, vaccines, and animal health additives aimed at improving animal well-being and productivity. The company operates across global markets, focusing on both companion animal health and farm animal health segments.
What sector is Elanco (ELAN) in?
Elanco (ELAN) is classified in the Health Care sector. Its industry is Animal Health. It trades on NYSE.
Who are Elanco's (ELAN) competitors?
Notable peers of Elanco (ELAN) include Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Idexx Laboratories and Ceva Santé Animale. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ELAN?
Yes — we hold 1 matched STOCK Act disclosure for ELAN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Elanco (ELAN) overbought or oversold right now?
Elanco (ELAN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ELAN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.